Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Latent Hit Identification in Primary Screening Data with Compound Set Enrichment

Thibault Varin, PostDoctoral Fellow, Novartis, Speaking at Medchem Europe 2011.
Date Posted: Thursday, December 01, 2011
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Novartis Provides Drug Candidate Compounds to TB Alliance
Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis.
Wednesday, August 20, 2014
Novartis Announces Portfolio Transformation
Company launches a major overhaul of its business, unveiling a series of multibillion-dollar deals with GSK and Eli Lilly.
Wednesday, April 23, 2014
Novartis and Collaborators Discover Novel Antimalarial Drug Candidate
New antimalarial drug candidate with novel mechanism of action has the potential to rapidly clear a Plasmodium infection upon administration of a single oral dose, as published in Science.
Tuesday, September 07, 2010
Novartis Gains Rights to Two Oral Targeted Investigational Therapies
Ex-US rights acquired for JAK inhibitor INCB18424 in Phase III development as first-in-class treatment for a life-threatening blood disorder.
Tuesday, December 01, 2009
Nuevolution Announces New Research Collaboration with Big Pharma
Partnership to use Nuevolution's Chemetics® technology for lead discovery.
Tuesday, September 01, 2009
Novartis Begins Shipment of Fluvirin® Seasonal Influenza Vaccine for U.S. Market Ahead of Schedule
Company is providing 30 million doses of Fluvirin vaccine to support the annual seasonal influenza vaccination campaign.
Thursday, August 06, 2009
FORMA Announces Collaboration with Novartis to Develop Inhibitors of Protein-Protein Interactions
FORMA will leverage its expertise to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology.
Tuesday, January 13, 2009
Dynavax Enters Into Supply and Option Agreement for Development of Universal Influenza Vaccine
Novartis will provide Dynavax a supply of trivalent influenza vaccine for both clinical trial use and vaccine sales.
Thursday, July 24, 2008
Scientific News
Laser Technique for Self-Assembly of Nanostructures
Researchers have developed a low-cost technique that holds promise for a range of scientific and technological applications.
Researcher Discovers Molecules That Kill Cancer, Protect Healthy Cells
This research shines a light on what happens to cells at the moment they become cancerous and the potential of femtomedicine to revolutionize cancer treatment.
Label-Free Binding Analysis Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Progress Towards A New Asthma Treatment
University of Queensland researchers are developing a new asthma treatment that targets the underlying cause of asthma, rather than just the symptoms.
Multiple Types Of Resistance To New Lung Cancer Drug Identified
Study shows genomic heterogeneity in mechanisms of resistance to TKI drugs.
Compound To Combat Malaria Parasite Identified
Study identifies non-mevalonate pathway for isoprenoid biosynthesis as key antimalarial drug target.
Are Chemical Safety Regulations Changing Your Laboratory?
GHS changes to country chemical regulations affect everyone.
Drugs that Activate Brain Stem Cells May Reverse Multiple Sclerosis
NIH-funded study identifies over-the-counter compounds that may replace damaged cells.
Allergy Drug Inhibits Hepatitis C in Mice
NIH study suggests alternative drug to treat virus.
Saccharin Shows Promise as Cancer Inhibitor
Researchers have found that the artificial sweetener can inhibit cancer cell growth.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters